03:18 PM Abstract No. 230 Predictors of overall and progression-free survival in patients with ocular melanoma metastatic to the liver undergoing Y90 radioembolization: a 15-year single-institution experience

Abstract

Results: 41 RE patients met the inclusion criteria. 55%(n¼23) were male with a mean age of 64 (range, 44-90). Patients received 1-3 lines of chemotherapy before RE. There was no difference in tumor markers, or primary site location (right vs. left) between the two groups. 24 patients (58%) were classified as high tumor burden and 42%(n¼17) as low tumor volume. Median PFS in the high group was 3 months (95% CI 1.8-12.9) and in low group was 6 months (95% CI 5.5-14.4). Objective response in low tumor burden group was CR (n¼10), PR (n¼7), SD (n¼4) and PD (n¼3) vs. in high tumor burden group CR (n¼0), PR (n¼4), SD (n¼6), and PD(n¼7). Stratification of objective response to Y90 by tumor burden demonstrated statistically significant difference between high and low with low tumor burden resulting in improved response (P¼0.007). Correlation between tumor burden and PFS demonstrated a significant difference (P< 0.039). Conclusions: Tumor burden can be used as an independent predictor of response and progression-free survival to Y90 of hepatic mCRC.

Long-Term Maintained Response to Selective Internal Radiation Therapy in an Oligometastatic Uveal Melanoma Patient Treated with Concomitant Anti-PD-1 Therapy

“…One of them (Levey at al.) [ 26 ] managed to prove a clear advantage in terms of overall survival (OS) when combining IT and SIRT: the median OS for those who received immunotherapy within 3 months of undergoing Y 90 was prolonged at 26.0 months, versus 9.5 months for the patients who did not ( p = 0.014). Median hepatic progression-free survival (PFS) was prolonged in patients treated with Y-90 and con-current immunotherapy at 10.3 months, versus 2.7 months for TARE only ( p = 0.002).…”